Clinical trials: Anti-vascular Endothelial Growth Factor
Macular Edema, Retinal Vein Occlusion
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
- Trial name
- BEACON (NCT04592419)
- Testing
- KSI-301, Aflibercept
- Where
- 141 sites in United States, Czechia and 10 more
- Volunteers
- 568 people
- Sponsor
- Kodiak Sciences Inc
Pain
Intravitreal Injection Site and Perceived Pain
The objective of this study is to explore the perception of pain during intravitreal injection related to the distance of the entry site from the limbus.
- Trial name
- NCT05640895
- Testing
- Intravitreal injection site
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Endophthalmitis
Endophthalmitis After Intravitreous Anti-VEGF Injections in Patients Receiving vs. Not Receiving Topical Antibiotics
This is a prospective case series which aims to determine the incidence of endophthalmitis following intravitreous anti-vascular endothelial growth factor (VEGF) injection comparing between eyes receiving post-injection…
- Trial name
- NCT02810587
- Testing
- Topical antibiotics following injection
- Where
- Thailand
- Volunteers
- 5,000 people
- Sponsor
- Chiang Mai University
Retinal Vein Occlusion, Macular Edema
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO).
- Trial name
- CRAVE (NCT01428388)
- Testing
- Intravitreal injection of bevacizumab, Intravitreal injection of ranibizumab (0.5 mg per dose)
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Barnes Retina Institute
Post-Injection Intraocular Pressure Spikes
Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy
In this study, investigators will be examining the intraocular pressure lowering effect of brimonidine 0.15% when administered 20min prior to intravitreal anti-VEGF injection.
- Trial name
- NCT03513172
- Testing
- topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Non-small Cell Lung Cancer
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well…
- Trial name
- NCT07111520
- Testing
- BNT326, Pumitamig
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 880 people
- Sponsor
- BioNTech SE
Colorectal Neoplasms
Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical
The purpose of this study is to determine whether Endostar pumping into vein with Thalidomide are more effective in the treatment of Advanced Colorectal Cancer (ACRC).
- Trial name
- NCT02748772
- Testing
- Two Anti-angiogenesis Drugs（Endostar and Thalidomide）, Pure chemotherapy（Xelox）
- Where
- 3 sites in China
- Volunteers
- 148 people
- Sponsor
- The First People's Hospital of Hefei
Neovascular Age-related Macular Degeneration, Macular Degeneration
Photodynamic Therapy for PDA in NV AMD
The purpose of this prospective observational study is to assess the potential clinical effects of adjunctive verteporfin photodynamic therapy (PDT) for persistent disease activity among patients with neovascular age-related…
- Trial name
- NCT02452840
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Duke University
Advanced Solid Tumor
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or…
- Trial name
- NCT07070232
- Testing
- BNT326, Pumitamig, Itraconazole
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 1,438 people
- Sponsor
- BioNTech SE
Diabetic Macular Edema
Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents
Diabetic retinopathy (DR) is considered the main etiology of blindness among working-age adults, and Diabetic macular edema (DME) is the main reason for vision loss related to DR .
- Trial name
- NCT06205979
- Testing
- Ranibizumab Injection [Lucentis], Aflibercept Injection [Eylea]
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Age-Related Macular Degeneration
Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
Phase 2 clinical trial, single site, randomized, subject-masked study to determine safety and efficacy of intravitreal injections of Sirolimus in subjects with wet Age-Related Macular Degeneration (wet AMD) with persistent…
- Trial name
- NCT02357342
- Testing
- Sirolimus, Standard of Care intravitreal injections of anti-VEGF
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Neovascular Age Related Macular Degeneration (AMD), Open Angle Glaucoma
TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection
This is a prospective, open label study assessing the 24-hour IOP patterns using TF in patients undergoing anti-VEGF injection for the treatment of neovascular AMD (age related macular degeneration).
- Trial name
- NCT01983579
- Testing
- Intraocular anti-VEGF injection, SENSIMED Triggerfish
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Sensimed AG
Wet Macular Degeneration, Age-related Macular Degeneration
Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.
This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related…
- Conditions
- Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02571972
- Testing
- Dorzolamide-timolol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wills Eye
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or…
- Trial name
- NCT06449209
- Testing
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide
- Where
- 64 sites in United States, Australia and 3 more
- Volunteers
- 110 people
- Sponsor
- BioNTech SE
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
A previous pilot study demonstrated that commonly available glaucoma drops (dorzolamide-timolol) might decrease the amount of chronic swelling in patient with wet age-related macular degeneration who have been receiving…
- Trial name
- DAWN (NCT03034772)
- Testing
- Dorzolamide-timolol, Artificial tears
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Wills Eye
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to…
- Trial name
- NCT00775411
- Testing
- dexamethasone, ranibizumab
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 44 people
- Sponsor
- Allergan
Peritoneal Cancer
Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis
The goal of this clinical research is to learn acceptable dosages of paclitaxel, oxaliplatin, and Avastin (bevacizumab) that can be given in combination to patients with advanced peritoneal carcinomatosis.
- Trial name
- NCT00491855
- Testing
- Bevacizumab, Oxaliplatin, Paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Diabetic Macular Edema
Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant
The dexamethasone 700 μg intravitreal implant (DEX-I) delivers dexamethasone gradually to the retina over time. It is an approved drug for the treatment of DME.
- Trial name
- P23-380 - INIT (NCT05978622)
- Where
- 54 sites in Belgium, China and 7 more
- Volunteers
- 236 people
- Sponsor
- AbbVie
Macular Edema
A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease
AURIGA is designed to collect data from routine clinical practice on the effectiveness and utilization of intravitreal aflibercept in the treatment of visual impairment due to diabetic macular edema (DME) or macula edema…
- Trial name
- AURIGA (NCT03161912)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- 11 sites in China, Egypt and 9 more
- Volunteers
- 2,481 people
- Sponsor
- Bayer
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in…
- Trial name
- DAZZLE (NCT04049266)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Czechia and 5 more
- Volunteers
- 559 people
- Sponsor
- Kodiak Sciences Inc